Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amateur, I'll just note for the benefit of newcomers that CYDY did not PR the Vyera deal on the morning of the 12/17/19 conference call. They announced it on the call and PR'd it immediately after.
I don't know what to expect today ... hope you are well and GLTU as always.
When even Adam F is tweeting about the ridiculous timing of the release, you know you have a problem.
bob, I didn't watch the presentation. What was the issue with the stats?
thanks.
Buy out, yes, because all outstanding warrants and options will be included..
The outstanding shares for any reverse split or uplist will just be those shares that are outstanding.
My understanding is the warrants and options stay in place.
Anyway you slice it though, still a lot of shares!
And again, CYDYs PR about BLA submission wasnt false when it was issued. But they have rolling review from the FDA, and they may have gotten comments to the data sets previously submitted. In other words, after the initial PR, the FDA came back and said, as part of their rolling review, we need you to make some changes to these data sets before we will consider the BLA fully submitted.
Again, the stat article is not fake news, but it is a half truth more than likely.
Unfortunately, it's not totally fake news. Check the fine print of the recent PR's. The company updated its PR regarding the BLA filing to say that it had to resubmit some data sets on May 11th based on comments received from the FDA to data sets submitted on March 12th.
The best lies have a very thin coating of truth.
The S-3 filing also says, in the note above the table from which you draw the share count numbers referenced in your post ...
Appreciate the responses - thanks!
Good deal. Thanks for following up and, again, for sharing thoughts. GLTU
Thanks Rockleo. Really appreciate you sharing.
Can you please clarify your point #2 for my benefit and the benefit of the board?
I take it to mean that NP's stock play was necessary to pay necessary company expenses (e.g., manufacturing) without raising additional funds at price levels and on terms that management deemed unacceptable.
Is that an accurate summary of SK's thoughts on #2?
Also, I think I missed the ID of Dr. UK?
Welcome. If you are serious about CYDY, I wouldn't waste your time on this board. There are other resources that are more worthwhile.
An S-3 registers shares that were previously unregistered so that those shares are ABLE to be sold if the shareholder would like to do so. The "selling shareholders" listed are simply those shareholders whose shares are being registered and thus become ABLE to be sold.
CYDY had a contractual obligation to register shares that were previously issued under valid SEC exemptions from registration.
An S-3 is not a filing indicating that the "selling shareholders" listed in the S-3 INTEND TO OR WILL SELL.
I'm always happy to answer any questions you have regarding basic SEC filings....
Excellent post.
Fair question. But if that's a fair question, it is also fair to ask who paid for the AF article, the culper report, etcetera.
There is always an agenda, from all sides.
Second that. I've often thought I would be happy to sign an NDA and never trade this stock again If I could just help them write the press releases (for free)!
I am not sure what he has less of, morals or credibility. in my mind, it's a neck and neck race to the bottom between the two.
Sadly, I agree 100%
If you do not play OTC stocks, then why are you commenting on a message board for an OTC stock? Do you plan to buy or sell CYDY? What is your strategy?
Your point?
It is a fake form 144. Anything filed with the SEC would show up on Edgar database.
A form 144 has to be filed with the SEC.
https://www.investopedia.com/terms/f/form144.asp
I literally just checked Edgar. There's nothing filed.
This is attempted stock manipulation plain and simple.
The form 144 is a fake report.
The filing that you should understand is yesterday's S3.
There were some posts on the board last night explaining that filing that you may find helpful. GLTU
Good, thank you for doing that.
Correct answer - we have a winner!
I agree with you amateur, and I'm very much looking forward to reviewing BP's peer-reviewed journal articles. It sounds like they have uncovered some fascinating things.
I would suggest you consider the source and its motives and focus on the science
We're on the same page. I agree with you 100%.
I tend to agree. FDA didn't reject BTD, but CYDY did tell us they needed to have a meeting with the FDA. Presumably to discuss further enrollment/data needed to support BTD request. Also, presumably that meeting has been cancelled due to COVID-19.
BTD is still VERY possible in mTNBC. Just need to be patient.
Amateur, the clinical trial sites are not the same as the treatment sites for emergency IND patients. The latter could be anywhere where a doctor has heard of the drug and requests it for the patient. GLTU
Kitana, I think the disclaimer at the top of the link said that all covid 19 manuscripts are automatically given rapid review and that as a result no other manuscripts are eligible for rapid review right now.
So I think it just gets rapid review automatically.
Not sure how I missed that. Thanks for bringing it to my attention. Definitely changes the way I view that statement, though the cynic in me is still skeptical! GLTU
Interesting.... Thanks for sharing.
Unfortunately, the other drug is likely tocilizumab
Interesting post. Thanks for your thoughts.
Not just a reply to your post, but for the benefit of the board (especially newer SH) when we are all running our models, remember the (I believe) aggregate 8.5% royalty owed to Progenics and Abbvie.
I sometimes forget about that when I'm doing back of the envelope calculations.
It doesn't affect your overall point though.
With some very realistic assumptions, the numbers get big very quickly. Good luck to you
Care to elaborate on your speculation?
Great posts. Thank you for your insights.
Filing I referenced in prior post:
https://ir.stockpr.com/cytodyn/sec-filings-email/content/0001702447-20-000011/primary_doc.html
Not just a reply to you but for the benefit of the board.
Check the subsequent filing. Patel, the new board member, already owned over 7 million shares and over 2 million warrants before joining the board.
A MAJOR shareholder just joined the board.
Which makes sense now, because I thought the initial option grant for joining the board was a pittance. Turns out, he doesn't need any extra incentive to perform...
I googled Fox 13 Dr. Jo. Looks like Tampa Bay.
I feel like I'm taking crazy pills at times too ...
"No way I'm lucky enough to be this heavily invested in a company that can do that."
Strong words Saltz and really well said.